Podium to Practice: ESMO® 2025 – Melanoma: SWOG S1801
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
1601O – 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801
Studies/trials discussed:
1601O – 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801
199 Bay Street #4000
Toronto, ON M5L 1A9
©2026 OncologyEducation a Think Research company. All rights reserved. Privacy Policy. Privacy Notice. Accessibility Statement. Cookies Policy.
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.